Accendra Health CEO Pesicka to Retire by Year-End

The Tip Desk · August 10, 2026 · 3 min read

The home-based care company said the Owens & Minor sale, a balance-sheet reset and management-structure changes were complete as the board began a successor search.

Accendra Health, Inc. (ACH) said President and Chief Executive Officer Edward A. Pesicka will retire by the end of 2026 after more than seven years with the company, and the board has begun a search for his successor.

The Richmond, Virginia-based provider of products, technology and services for care beyond the hospital framed the leadership change as the next step after a series of corporate transactions. Pesicka said the divestiture of Owens & Minor, a balance-sheet optimization transaction, and recent changes to the company’s management structure were complete. He said he may serve in an advisory capacity beyond his planned retirement date to help with the transition.

Mark Beck, chair of the board, said Pesicka stabilized the company on arrival, led a rapid expansion of personal protective equipment production during the pandemic, and then guided the transformation into a pure-play home-based care company. The board said it maintains a succession-planning process and had previously identified potential candidates with the capabilities to succeed Pesicka.

The company scheduled an investor conference call for August 10, 2026, to discuss second-quarter 2026 financial results.

Pesicka’s tenure as chief executive spans the period in which Accendra completed the sale of its Products & Healthcare Services business, Owens & Minor, on December 31, 2025. After that close, continuing operations primarily represented what had been the Patient Direct segment and certain functional operations. In the fourth quarter of 2025, continuing-operations revenue was $709.0 million, up from $695.0 million a year earlier. Adjusted EBITDA from continuing operations was $90.0 million, and free cash flow was $18.3 million.

For the full year 2025, continuing-operations net revenue was $2.8 billion, which the company described as 3% growth versus the prior year. Operating cash flow for the year was $154 million.

In the first quarter of 2026, continuing-operations net revenue was $627.8 million, down from $673.9 million a year earlier. GAAP loss from continuing operations widened to $6.5 million from $3.8 million a year earlier. Adjusted net loss from continuing operations was $3.1 million, versus $23.2 million of adjusted net income a year earlier. Adjusted EBITDA from continuing operations fell to $58.4 million from $96.0 million, and free cash flow turned negative at $2.0 million from $35.6 million.

Pesicka said first-quarter results were aligned with the company’s expectations as it continued its transformation into a pure-play home-based care company, and that transition services and other separation activity related to the Owens & Minor divestiture were on track.

On May 11, 2026, Accendra announced a more than $1.5 billion comprehensive balance-sheet optimization transaction with commitments from existing creditors. The package would pay off 2027 maturities, extend the revolving credit facility, reduce leverage, and extend other maturities. The company planned to effectuate the transaction in the near term.

After the first quarter, the company affirmed its prior full-year 2026 guidance for net revenue and adjusted EBITDA.

Pesicka’s retirement announcement came after those capital-structure steps and the Owens & Minor close, the same sequence he cited as the reason the timing was right for a leadership change. The board said it will use its existing succession work to evaluate and select the next president and CEO. Pesicka will also step down from the board before the end of the year.

Accendra described itself as a nationwide provider that connects patients, providers and insurers, with the Apria and Byram brands supporting a portfolio spanning diabetes, sleep health, wound care, respiratory care, urology and ostomy.